Convertible Notes vs Safes vs Priced Rounds: Australian Legal & Cap-table Comparison

Convertible notes vs SAFEs vs priced rounds is the first strategic decision most Australian founders confront when raising seed capital, and getting it wrong can quietly reshape your cap table for years. Each instrument carries different legal characterisations under the Corporations Act 2001 (Cth), different investor protections, and very different dilution outcomes when conversion eventually happens. With more sophisticated angel capital circulating and continued regulatory attention on how offers are made, the temptation to copy a US template without local legal review is both greater and more dangerous. This guide compares the three instruments through an Australian lens, conversion mechanics, cap-table math, ASIC and disclosure traps, and the negotiation points that keep your next round simple.

Quick summary: pick the right tool

The choice between convertible notes vs SAFEs vs priced rounds usually comes down to four trade-offs: speed and cost, investor protection, founder dilution, and compliance risk. Convertible notes and SAFEs are both deferred pricing instruments, they let you take money now and set the valuation later, avoiding a lengthy negotiation over what the company is worth. A priced round, by contrast, sets the valuation today and issues shares immediately.

SAFEs are typically the fastest and cheapest to execute because they are short contractual documents with no interest, no maturity date and no repayment obligation. Convertible notes sit in the middle: they are typically debt instruments that accrue interest and carry a maturity date, giving investors more protection but adding complexity and, potentially, a repayment liability if conversion never triggers.

Priced rounds are the most expensive and slowest but deliver the greatest certainty. Everyone knows exactly who owns what the day the round closes, and investors receive full shareholder rights. For founders, the practical answer to “which is better” is rarely absolute, it depends on how much traction you have, how much certainty investors demand, and how carefully you model the eventual cap-table impact. What matters most is that the mechanics are clear and Australia-compliant before anyone signs.

What are convertible notes, SAFEs and priced rounds?

Understanding convertible notes vs SAFEs vs priced rounds starts with understanding what each instrument actually is in legal terms, because the legal character drives everything downstream, from tax to disclosure to what happens in an exit.

A convertible note is generally a debt instrument. The investor lends the company money, that loan usually accrues interest, and instead of being repaid in cash it converts into equity on a defined future event, most commonly a qualifying priced round. It typically has a maturity date, meaning if conversion has not happened by then, the debt may become repayable (or is renegotiated).

A SAFE (Simple Agreement for Future Equity) originated in the United States but is now widely used across Australian startups. It is typically not debt and not equity at the point of signing, it is a contractual right to receive shares in the future on defined triggers. There is no interest, no maturity date and generally no repayment right, which makes SAFEs founder-friendly but also legally novel in the Australian context.

A priced round is a straightforward equity raise. The company and investors agree a valuation, shares are issued immediately at an agreed price, and the investor becomes a shareholder on day one with all the rights recorded in a shareholders’ agreement and updated constitution.

How each instrument works

• Convertible note. Money in as a loan; interest usually accrues; converts to shares at a discount and/or subject to a valuation cap on a qualifying financing; maturity date creates a repayment or renegotiation trigger if no round occurs.
• SAFE. Money in as a contractual advance; typically no interest and no maturity; converts to shares on a defined equity financing, typically using a valuation cap, a discount, or both; some variations include a most-favoured-nation (MFN) clause.
• Priced round. Valuation agreed now; shares issued immediately at the agreed price per share; investor signs the shareholders’ agreement and receives governance and economic rights straight away.

Legal & regulatory considerations in Australia

Any comparison of convertible notes vs SAFEs vs priced rounds is incomplete without the regulatory overlay. In Australia, fundraising is governed principally by the Corporations Act 2001 (Cth) and administered by the Australian Securities and Investments Commission (ASIC). The central question for every instrument is whether an offer triggers disclosure obligations and how the instrument is characterised.

Is a SAFE a “security” or “financial product” in Australia?

This is the most under-appreciated risk with SAFEs. Because the SAFE was designed for the US regulatory environment, its treatment under Australian law depends heavily on the specific terms and facts. Depending on drafting, a SAFE may be characterised as a security or financial product, bringing it within the disclosure and licensing framework of the Corporations Act, or as something closer to a debt or equity interest. Assuming a SAFE sits outside Australian securities regulation simply because it did in the US is a mistake. Characterisation under Australian law generally turns on substance, not labels, so local legal review of the exact terms is essential before you rely on any exemption.

Offer and disclosure obligations under the Corporations Act

Offering securities to retail investors generally triggers disclosure obligations, a prospectus or other disclosure document, under the Corporations Act. Many early-stage raises avoid this by relying on exemptions such as offers to sophisticated or professional investors, or the small-scale personal offers exemption (the “20/12/2 rule”). To rely on these exemptions safely you must verify each investor’s eligibility and retain the supporting documentation, such as an accountant’s certificate where required. Failing to check investor status before accepting money is one of the most common and most serious compliance errors in Australian fundraising, and it applies equally whether you use a convertible note, a SAFE or a priced round.

ASIC and crowdfunding considerations

Australia has a dedicated crowd-sourced funding (CSF) regime with its own eligibility criteria, investment caps and disclosure requirements. If you intend to raise from the public through a licensed CSF platform, the choice of instrument and the associated disclosure obligations change materially. Convertible instruments used outside a CSF platform do not benefit from that regime’s tailored concessions, so founders should be clear about which pathway they are on before structuring the raise.

Conversion mechanics: valuation caps, discounts, interest, maturity and triggered conversions

The heart of any convertible notes vs SAFEs vs priced rounds analysis is the conversion math. This is where founders most often lose ownership they did not expect to lose, because the interaction of caps, discounts and interest is not intuitive.

Convertible note conversion formulas

On a qualifying financing, a convertible note typically converts into shares at the more favourable of two mechanisms for the investor:

• Valuation cap. Conversion price = valuation cap ÷ fully diluted shares before conversion.
• Discount. Conversion price = next-round price per share × (1 − discount rate).

Worked example (illustrative). Suppose an investor advances $500,000 under a note with a 20% discount and a $5,000,000 valuation cap, accruing 8% simple interest. Eighteen months later the company raises a Series A at a $10,000,000 pre-money valuation, with 8,000,000 shares outstanding, a Series A price of $1.25 per share.

• Accrued interest: $500,000 × 8% × 1.5 years = $60,000, so the total converting amount is $560,000.
• Discount price: $1.25 × (1 − 0.20) = $1.00 per share.
• Cap price: $5,000,000 ÷ 8,000,000 = $0.625 per share.
• The cap price is lower, so it applies: $560,000 ÷ $0.625 = 896,000 shares.

Note how the valuation cap, not the discount, governs the outcome here, a common result when the company’s valuation rises well above the cap. (Actual mechanics depend on how the fully diluted share base is defined in the instrument.)

SAFE conversion mechanics

SAFEs convert using the same building blocks but typically without interest or maturity. Variations include:

• Cap-only SAFE. Converts at the valuation cap divided by fully diluted shares.
• Discount-only SAFE. Converts at the next-round price less the agreed discount.
• Cap-and-discount SAFE. Converts at whichever gives the investor more shares.
• MFN SAFE. No cap or discount initially, but the investor may adopt the most favourable terms granted to any later SAFE holder.

Worked example (illustrative). A $500,000 cap-and-discount SAFE with a 20% discount and a $5,000,000 cap, converting in the same Series A above: the cap price of $0.625 beats the discount price of $1.00, so $500,000 ÷ $0.625 = 800,000 shares. Because there is no accrued interest, the SAFE investor receives fewer shares than the note investor for the same headline terms.

Conversion triggers and maturity

Notes and SAFEs both typically convert automatically on a qualified financing, a priced round above a defined threshold. The critical difference is maturity. A convertible note typically carries a maturity date; if no qualifying round happens by then, the note may become repayable, convert at a fallback valuation, or require renegotiation. This repayment risk is a genuine liability that can push a cash-strapped company toward insolvency. A SAFE typically has no maturity, so it simply waits, which removes the repayment risk but also removes the deadline pressure that can motivate investors and founders alike.

Cap-table impact and worked examples for convertible notes vs SAFEs vs priced rounds

Cap-table dilution is where the abstract choice between convertible notes vs SAFEs vs priced rounds becomes concrete. Two scenarios show how the same raise produces different ownership outcomes depending on the eventual valuation.

Example A: low pre-money when the instrument converts

Assume founders hold 8,000,000 shares and raise $500,000 via a note or SAFE with a $5,000,000 cap and 20% discount. The company later raises a modest Series A at a $6,000,000 pre-money valuation. Because the valuation is only slightly above the cap, the cap still governs and the converting investor receives roughly 800,000–900,000 shares depending on interest. Founders are diluted meaningfully because the cap effectively prices the early money at a low valuation, the reward for taking the early risk.

Example B: high pre-money when the instrument converts

Same inputs, but the Series A closes at a $20,000,000 pre-money valuation. Now the gap between the cap and the round price is large, so the cap dramatically favours the early investor and produces a much larger ownership percentage than the discount would. This is where founders are frequently surprised: a low cap agreed casually at seed stage can hand an early cheque a disproportionate slice of the company once the business succeeds.

The practical lesson: a valuation cap is not a “nice to have”, it is one of the most powerful levers on future founder dilution. Model at least two conversion scenarios before agreeing any cap.

Quick comparison: convertible notes vs SAFEs vs priced rounds

Investor protections and governance

Governance is one of the sharpest differentiators in the convertible notes vs SAFEs vs priced rounds decision. Deferred instruments typically give investors far fewer rights until conversion, whereas a priced round hands over real control mechanisms immediately.

Typical priced-round investor terms

In a priced round, expect investors to seek a package of rights recorded in the shareholders’ agreement, which may include:

• Information rights, regular financial and management reporting.
• Pre-emption rights, the right to participate in future rounds to protect their percentage.
• Anti-dilution protection, adjustment if later shares are issued at a lower price.
• Board seat or observer rights, direct or indirect participation in decision-making.
• Liquidation preference, priority return on an exit.
• Reserved matters / vetoes, consent rights over key decisions.

Protective clauses to consider for notes and SAFEs

Because notes and SAFEs generally lack these rights before conversion, investors sometimes negotiate them through side letters. Common additions include information rights, pro-rata participation rights, and, for notes, security over company assets. Founders should weigh these carefully: granting extensive rights on a deferred instrument can erode the very simplicity that made the instrument attractive, and can complicate the eventual priced round when those rights must be reconciled with the new shareholders’ agreement.

Securities compliance traps & common drafting mistakes

Many disputes in convertible notes vs SAFEs vs priced rounds arise not from the deal itself but from sloppy drafting and compliance shortcuts. The following traps recur across Australian raises.

Checklist for compliance

• Confirm and document each investor’s sophisticated or professional status before accepting funds, retain accountant’s certificates where relied upon.
• Determine whether the offer triggers disclosure obligations under the Corporations Act, and whether a genuine exemption applies.
• Check whether the instrument could be characterised as a security or financial product requiring licensing or disclosure.
• Keep a clean register of every instrument, its terms and its conversion status.

Red flags in common templates

• US SAFE forms used without Australian legal review, a significant risk, because US regulatory assumptions do not carry over.
• Overly broad MFN clauses that unintentionally upgrade one investor to another’s better terms.
• Interest roll-up provisions that quietly inflate the converting amount and founder dilution.
• Vague or undefined “qualified financing” thresholds, which create arguments about whether conversion has been triggered.
• Ignoring the interaction between conversion events and employee equity plans.

Never adopt a foreign template without local counsel confirming its characterisation and compliance under Australian law.

Tax and employee-equity consequences

Tax treatment is a further point of divergence in the convertible notes vs SAFEs vs priced rounds comparison, and it should be assessed with professional advice rather than assumed.

Tax and ESS interactions

Convertible notes are frequently analysed under the debt/equity rules in the tax law while they remain outstanding, given their interest and repayment features, though the precise treatment depends on the terms. SAFEs, being neither classic debt nor equity, require careful analysis of when a taxing event might arise. Conversion itself, and the issue of new shares, can also interact with a company’s employee share scheme (ESS) arrangements, because dilution and changes in share value can affect the tax outcomes for employee participants. Founders running an ESS should map how each fundraising instrument and its conversion will flow through to their team’s equity before committing to terms, and should obtain specific tax advice.

Negotiation & drafting checklist, what founders should ask for

Whatever your choice among convertible notes vs SAFEs vs priced rounds, disciplined drafting protects your future flexibility.

Sample term sheet items to include

• Valuation cap and/or discount, with modelled dilution under multiple future valuations.
• Clear “qualified financing” definition, including the minimum threshold that triggers conversion.
• Precise conversion mechanics, which price applies, how interest (if any) is treated, and the fully diluted share base used.
• Maturity treatment (for notes), repayment, extension or fallback conversion.
• Investor protections and information rights, scoped so they do not over-encumber the company.
• Transfer restrictions, to control who ends up on the register.
• Governing law and dispute resolution, Australian law and forum.
• MFN scope (for SAFEs), carefully bounded.

When to choose a priced round

A priced round becomes the better answer when the conditions support agreeing a real valuation. Consider it when the business has revenue traction that makes a valuation defensible, when investors want genuine governance and shareholder rights rather than a deferred promise, when you need a clean and certain equity structure ahead of potential M&A or an eventual ASX listing, or when multiple convertible instruments are already outstanding and a priced round is needed to reset the cap table into a clear, single structure. In those situations the extra cost and time of a priced round buy certainty that deferred instruments cannot.

Conclusion & next steps

The choice between convertible notes vs SAFEs vs priced rounds is never purely a matter of speed or fashion, it can influence who owns your company, what rights investors hold, how you are taxed, and whether your raise complies with the Corporations Act and ASIC requirements. Model the conversion math under several valuations, verify every investor’s status, and never adopt a foreign template without Australian legal review. Before you sign any instrument or accept any funds, obtain tailored corporate and tax advice so your current raise supports, rather than complicates, your next round and your eventual exit.

Sources

1. Corporations Act 2001 (Cth)
2. Australian Securities and Investments Commission (ASIC)
3. ASIC, Crowd-sourced funding
4. Australian Taxation Office, Employee share schemes (ESS)
5. Australian Securities Exchange (ASX), Rules frameworks